20/01/2025
Mikrobiomik Health Company has reached a new milestone by being recognised twice at the Quality Innovation Awards 2024 in the international phase: Best Innovation in the Healthcare Sector and the highest distinction of the competition, Innovation of Innovations.
In this 18th global edition, a total of 557 innovations participated, of which only 23 were awarded after a rigorous international evaluation process. Criteria considered included novelty, usability, customer orientation, efficacy and learning, with companies from different countries such as China, Hungary, Finland, Thailand, Turkey and Spain receiving awards.
MBK-01 is the award-winning innovation, our investigational biological medicine based on gut microbiota, designed to treat severe Clostridioides difficile infections without the use of conventional antibiotic treatments. This pioneering therapy represents a significant advance in the struggle against antimicrobial resistance, and a safe and effective solution for thousands of patients.
At the international QIA awards the projects reach this global phase after having been awarded in national stages, with eight different categories and a top award that represents the best innovation in all categories. Mikrobiomik has been chosen as Innovation of Innovations, positioning the company as a world leader in healthcare innovation.
The official award ceremony will be held in May 2025 in Bangkok, organized by the Productivity Institute of Thailand, where Mikrobiomik will represent the Basque Country and Spain.
We express our gratitude and dedicate this achievement to our talented team, who work every day to develop innovative therapies that transform patients’ lives and contribute to the sustainability of the healthcare system. This milestone reinforces our commitment to excellence and microbiota.
For more information about the award and to get the completed list of winners, visit Quality Innovation Awards.
